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The transcription factor TFIID is a multiprotein complex that includes the TATA box binding protein (TBP)
and a number of associated factors, TAFII. Prodos (PDS) is a conserved protein that exhibits a histone fold
domain (HFD). In yeast two-hybrid tests using PDS as bait, we cloned the Drosophila TAFII, dTAFII16, as a
specific PDS target. dTAFII16 is closely related to human TAFII30 and to another recently discovered Dro-
sophila TAF, dTAFII24. PDS and dTAFII24 do not interact, however, thus establishing a functional difference
between these dTAFs. The PDS-dTAFII16 interaction is mediated by the HFD motif in PDS and the N terminus
in dTAFII16, as indicated by yeast two-hybrid assays with protein fragments. Luciferase-reported transcription
tests in transfected cells show that PDS or an HFD-containing fragment activates transcription only with the
help of dTAFII16 and TBP. Consistent with this, the eye phenotype of flies expressing a sev-Ras1 construct is
modulated by PDS and dTAFII16 in a gene dosage-dependent manner. Finally, we show that PDS function is
required for cell viability in somatic mosaics. These findings indicate that PDS is a novel transcriptional
coactivator that associates with a member of the general transcription factor TFIID.
One of the first events in transcription of protein-encoding
genes is the assembly of a preinitiation complex that contains
RNA polymerase II and general transcription factors such as
TFIIA, TFIIB, TFIID, TFIIE, TFIIF, TFIIH, and TFIIJ (24,
52, 56). Assembly is thought to be a sequential process initiated
by the nucleation of transcription factors to core promoters or,
alternatively, the attachment of preformed complexes, holoen-
zymes, to target DNA sequences (36).
TFIID is a multiprotein complex formed by the TATA-
binding protein (TBP) and several TBP-associated factors,
TAFIIs (23, 31, 38, 66, 70). TAFIIs are named according to
their apparent or estimated molecular weight (e.g., TAFII30,
TAFII105). They are present not only in TFIID but also in
other complexes that play additional roles in chromatin remod-
eling and gene transcription, such as SAGA, PCAF, and TFTC
(22, 43, 51, 63, 75). Their presence in multiple protein com-
plexes reflects a variety of functional roles and protein inter-
actions. Some TAFIIs are thought to mediate promoter recog-
nition and selectivity (8, 61, 69). Human TAFII250 exhibits
histone acetylase and protein kinase activities that modulate
chromatin structure as well as the activity of general transcrip-
tion factors (11, 46, 49). Other TAFIIs are thought to act as
cofactors, since they associate with specific transcription acti-
vators. For example, hTAFII130 and its Drosophila homologue,
dTAFII110, interact with Sp1 (29, 57, 65) and with the cyclic
AMP response element-binding protein (13, 14, 58). In addi-
tion, hTAFII105 interacts with NF-kB (77). In vitro experi-
ments using reconstituted TFIID complexes demonstrated a
synergistic interaction between two activators, Bicoid and
Hunchback, and specific TAFIIs, TAFII110 and TAFII60 (59).
In vivo studies in Drosophila support the hypothesis that
TAFIIs may serve as targets for enhancer-binding proteins (54,
78). On the other hand, TAFIIs may also serve to mediate
signaling pathways; this is the case for hTAFII55, hTAFII30
and hTAFII28, which bind to nuclear receptors for thyroid
hormone, estrogen, and retinoic acid, respectively (37, 44).
Likewise, hTAFII31 interacts with p53 (40) whereas dTAFII40
interacts with VP16 (21, 35) and p53 (67). TAFIIs thus con-
tribute to gene regulation, acting as cofactors in a wide reper-
toire of interactions with transcription factors.
Nonetheless, under certain conditions, TAFIIs may not be
obligatory components of activated transcription. Yeast and
HeLa cells depleted of major TAFIIs can form preinitiation
complexes in a single-round transcription assay (47, 50, 71).
Although it is possible that TAFIIs are not always required for
transcription initiation, it is clear that they are essential for the
functional expression of specific genes. In yeast and mammals,
TAFII mutations cause cell cycle arrest at phases specific to
each TAFII (1, 42, 45, 72, 73). In Drosophila, mutations in
TAFII110, TAFII250, and TAFII60 yield lethal phenotypes
(FlyBase, on http://flybase.bio.indiana.edu). For any particular
type of TAFII, sequences are significantly conserved among
yeast, flies, and humans (23, 66). Thirteen are known so far,
and this number is not likely to increase much further since the
identification has been carried out mostly through direct bio-
chemical purification of whole complexes. Although several of
them are usually present in any given complex, it seems that
the exquisite control of gene transcription would require a
larger repertoire of regulators. It is in this context that the
PDS-TAFII16 interaction described here becomes relevant.
prodos (pds) is a recently discovered vital gene from the 16F
cluster in the X chromosome of Drosophila (55). The corre-
sponding protein, Prodos (PDS) (submitted to the EMBL da-
tabase under accession number Y15513), is rich in proline
residues and contains a histone fold domain (HFD). This motif
is thought to mediate DNA-protein and protein-protein inter-
actions (2) and is found in the four core histones (4) as well as
in several TAFIIs (6, 18, 30, 76). The pds gene is expressed
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throughout development in all tissues analyzed, and the pro-
tein localizes to nuclear extracts (our unpublished data). The
conserved sequence and the general expression of the gene
suggested a basic role in cell biology; we thus set out to identify
proteins that might interact with PDS. The yeast two-hybrid
test led to the cloning of a new Drosophila TAFII, dTAFII16,
with significant homology to human TAFII30. We report the
characterization of this member of the TAFII family in Dro-
sophila and its physical interaction with PDS in vivo and in
vitro through the N terminus and the HFDs, respectively. We
also demonstrate that this association activates gene transcrip-
tion in transfected cells and that both proteins modulate the
expression of a gene construct in the organism.
MATERIALS AND METHODS
Fly strains and genetic procedures. The mutation pds2270 is an ethyl meth-
anesulfonate (EMS)-induced allele of pds, and pds88 is a P element insertion
located 17 bp upstream of the ATG initiation site in the transcription unit (our
unpublished data). Deletions Df(1)88-6 and Df(1)88-2 were generated by remo-
bilization of the P insert and characterized by genetic and molecular procedures.
Df(1)88-6 deletes approximately 4 kb from the insertion site toward the telomere
and removes the adjacent vital gene, HL-XIV, but not scully (55, 68). Df(1)88-2
deletes from the insertion site toward the centromere without affecting the
adjacent gene, HL-VII. The pds1 transgene was supplied by the genomic frag-
ment E6L, which contains the complete open reading frame (ORF) and is able
to rescue the pds phenotype (55). Two independent viable insertions of genomic
transformants, T(2)E6L and T(3)E6L, in the autosomes were tested, yielding the
same results. The Df(2)N6 and Df(2)N19 chromosomes were from the Bloom-
ington Stock Center (Indiana University, Bloomington, Ind.). These deficiencies
delete the dTAFII16 gene, as we confirmed by PCR. The sev-Ras1V12 construct
used was from the CyO-CR2 chromosome, provided by the Umea stock center
(Umea University, Umea, Sweden). Enhancers in sev-Ras1V12 consist of three
copies of the genomic fragment from 7134 to 7833, whereas those in sE-raf torY9
and sev-hsp-ro correspond to two copies of the fragment from 7319 to 8536 (3, 7).
The sev promoter is the fragment from the sevenless gene from 2966 to 88,
whereas the hsp promoter is the fragment from the hsp70 gene from 2250 to 90.
The sE-raf torY9 and sev-hsp-ro constructs were provided by E. Hafen (Zu¨rich
University, Zu¨rich, Switzerland). Scanning electron micrographs were obtained
using Philips XL-30 equipment. Mosaics were generated by X-ray-induced re-
combination in two genotypes, y w pds2270/f 36a and y w pds2270/M(1)n. In the first
case, most crossovers are expected to occur between the centromere and the pds
locus because of the large amount of intervening DNA. These crossovers generate
twin spots that should grow to the same size. In the second case, the mutant clones
have a growth advantage over their adjacent nonmutant cells, the M1 condition (15).
Plasmid constructs. All plasmids used in the yeast two-hybrid assays were
generated by PCR using suitable oligonucleotides and compatible restriction
sites. The resulting products were cloned into pACT2 and pAS2-1, which encode
the Ga14 activation domain and DNA-binding domain, respectively (Clontech).
To generate expression vectors for the fusion protein between glutathione-S-
transferase (GST) and PDS, GST-PDS, full-length pds cDNA was SmaI-EcoRI
digested from pAS2-1–PDS and cloned into pGEX. His-tagged full-length
dTAFII16 cDNA was likewise amplified by PCR and cloned into pRSET. TBP
and PDS were fused to a triple HA epitope tag, and dTAFII16 was fused to six
myc epitope tags at the start codon by PCR and cloned into RactHAdh (64). The
fusion product of PDS and the Ga14 DNA-binding domain was amplified from
pAS2-1–PDS and subcloned into RActHAdh. Constructs (G4)5-HSV-TK-Luc
and pPac-bgal were a gift of R. Tjian (University of California, Berkeley, Calif.).
We generated the construct sev-Luc by replacing the (G4)5-HSV-TK region of
the previous vector with the same regulatory (enhancer and promoter) sequences
of the sev-Ras1V12 construct (see above). The sev promoter was obtained from
vector pSP/HSS and the enhancers were from pSE8/DM30, supplied by D. A.
Wassarman (National Institutes of Health, Bethesda, Md.). All plasmids were
verified by DNA sequencing. Further details of construct procedures are avail-
able on request.
Yeast two-hybrid assay. The full-length PDS cDNA was used as bait. The
cDNA was cloned in plasmid pAS2-1 and introduced into the yeast strain Y190.
Colonies expressing the Ga14 DNA-binding domain fused to PDS were identi-
fied by immunoblotting with anti-PDS antibody. The second component of the
assay, the Ga14 activation domain, was supplied as an embryo cDNA library in
pGAD10 (Clontech). The subsequent transformation followed standard proce-
dures (27). A total of 1.4 3 107 library transformants were screened in this
manner.
Validation of yeast two-hybrid transformants. Of 312 transformants able to
grow in synthetic complete (SC) medium lacking histidine, only 76 contained
plasmids that activated lacZ transcription. To further eliminate false positives,
we provoked the loss of “bait” plasmids by streaking the transformants on SC
medium containing 2.5 mg of cycloheximide per ml (27). Plasmid loss was
verified by replica plating on SC medium lacking tryptophan and leucine. Trans-
formants were mated subsequently to Y187 yeast strains containing pAS2-1–
PDS, pAS2-1 alone, or pLAM59-1 (which expresses a fusion of Ga14 DNA-
binding domain and human lamin C). Eleven false positives were discarded since
they could activate lacZ transcription in the absence of PDS. Analysis showed
that they all encoded typical false positives (28). The remaining clones contained
plasmids that activated lacZ transcription only in the presence of the Ga14
DNA-binding domain fusion and PDS but not in the presence of pAS2-1 alone
or pLAM59. In addition, the interaction persisted after plasmid swapping be-
tween PDS and the isolated positive clones. Since they fulfilled all possible
controls of the yeast two-hybrid assay, we therefore considered the resulting 69
clones to be true positives.
Northern blot analysis and DNA cloning. Poly(A)1 mRNA was isolated using
a QuickPrep Micro mRNA purification kit (Pharmacia Biotech). mRNA (5 mg)
from each sample was loaded on 1.5% agarose–formaldehyde gels and trans-
ferred to nylon membranes (Bio-Rad). The probe was [g-32P]dATP radiolabeled
by the random-priming method (12). Transcript size was estimated using RNA
markers (Gibco-BRL). The partial cDNA found in the yeast two-hybrid assay
was used as a probe to screen an adult head lgt11 cDNA library (from E.
Meyerowitz, Caltech) at high stringency.
Immunological procedures. To immunize rabbits, the His-dTAFII16 fusion
protein was affinity purified using Ni-nitrilotriacetic acid agarose column (Qia-
gen). The anti-dTAFII16 monospecific antibody was affinity purified from crude
sera using a GST-dTAFII16 column (Pharmacia Biotech) (26) and used for
immunoblotting and immunostaining. Whole embryos and third-instar larvae
were dissected and fixed for 30 min in freshly prepared 4% paraformaldehyde in
phosphate-buffered saline (PBS). Specimens were incubated in crude rabbit
serum (1:1,000) or monospecific anti-dTAFII16 (1:200) overnight at 4°C in PBT
(0.1% Triton X-100 in PBS), thoroughly washed in PBT, and incubated for 1 h
at room temperature in secondary anti-rabbit immunoglobulin G antibody con-
jugated to Cy3 (Amersham). Preparations were mounted in PBS-glycerol (1:1)
and viewed under a confocal microscope (Leica). The anti-myc antibody (1-
9E10.2) was a gift of S. Pons (Instituto Cajal, Madrid, Spain), and the anti-HA
antibodies (rabbit Y-11 and mouse F-7) were from Santa Cruz Biotechnology.
GST pull-down experiments. The procedure used for the GST pull-down assay
was essentially as described elsewhere (53). Briefly, GST or GST-PDS proteins
(5 mg) immobilized on agarose resin (Pharmacia Biotech) were washed exten-
sively with LBST-100 buffer (25 mM HEPES-KOH [pH 7.9], 100 mM NaCl, 6%
glycerol, 5 mM MgCl, 1 mM dithiothreitol, 0.05% Triton X-100, 1 mM phenyl-
methylsulfonyl fluoride, 5 mM EDTA). His-dTAFII16 fusion protein (5 mg) was
added to the resins, and the interaction assay was carried out in a final volume
of 300 ml (for 2 h at 4°C) with gentle shaking. The beads were washed four times
with increasing NaCl concentrations (LBST-100, LBST-300, and LBST-500), and
the bound proteins were analyzed by immunoblotting using anti-dTAFII16 anti-
body.
Cell transfection and immunoprecipitation. Schneider line 2 cells were trans-
fected by the calcium phosphate method (9) at a density of 6 3 106 cells per
plate, using 5 mg of plasmid DNA for transfection. After 48 h, the cells were
harvested by three freeze-thaw cycles in buffer A (10 mM HEPES-KOH [pH 7.6],
100 mM NaCl, 10% glycerol, 8 mM MgCl, 1 mM dithiothreitol, 1 mM phenyl-
methylsulfonyl fluoride, 0.2 mM EDTA) if they were used for immunoprecipi-
tation or in reporter assay buffer (Promega) if they were used for determination
of luciferase activity. A 20-ml volume of cleared lysate was used for each lucif-
erase (Promega) and b-galactosidase assay, and luciferase activity was normal-
ized to that of b-galactosidase. For immunoprecipitation, 100-ml volumes of cell
extracts were incubated (for 2 h at room temperature) with 2 mg of the indicated
antibody in buffer A to a final volume of 400 ml. Following this, 20 ml of protein
A/G agarose (Santa Cruz Biotechnology) was added, and the incubation was
continued for 1 h at 4°C. The resin was extensively washed with buffer A, and the
bound material was analyzed by immunoblotting. Analysis of the potential in-
teraction is complicated by the fact that the protein constructs, HA-PDS and
myc-dTAFII16, have molecular weights very similar to those of the heavy and
light immunoglobulin G chains respectively. To avoid this problem, we immu-
noprecipitated them with a rabbit anti-HA polyclonal (Y-11) and analyzed the
result with mouse monoclonal anti-HA (F-7) and anti-myc (1-9E10.2) antibodies.
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Nucleotide sequences accession numbers. dTAFII16 and dTAFII24 sequences
have been submitted to the EMBL database under accession numbers AJ237968
and AJ276419, respectively.
RESULTS
PDS interacts with a new Drosophila TAFII. To identify pro-
teins that might interact with PDS, we carried out a yeast two-
hybrid screen using a previously isolated (our unpublished
data) full-length pds cDNA as bait (16). Of 1.4 3 107 clones
screened, 69 true positives were isolated from the initial 76
transformants (see Materials and Methods). On sequencing,
all 69 clones were found to contain an identical insert of 485
bp. This large number of clones probably results from the high
efficiency of the transformation process. Using this insert as a
probe, we screened an adult head cDNA library and isolated a
transcript 17 bp longer, which includes a putative translation
start site. A polyadenylation consensus signal is located at
position 482 (74), but no splice signals are found (48), and
comparison with the corresponding genomic sequence does
not reveal alternative splicing. Furthermore, expressed se-
quence tag (EST) database searches revealed one EST (acces-
sion number AI388776) with a sequence identical to that of our
cDNA, which was reported to the EMBL database under
accession number AJ237968. A more recent report indicates
the presence of a longer (770-bp) cDNA (accession number
AJ243837) (19). The ORF in both sequences, however, are
coincident, and the discrepancy between the two mRNA sizes
[0.7 and 0.95 kb respectively, including the poly(A) tracts]
pertains to the 59 untranslated region only. The conceptual
translation of the single ORF produces a 146-amino-acid pro-
tein with significant identity to human TAFII30 (Fig. 1). The
theoretical molecular mass of the Drosophila protein is 16
kg mol21. Based on this value and the sequence identity to
hTAFII30, we named the gene dTAFII16. Northern blot anal-
yses indicate that the gene is expressed as a single mRNA band
detected throughout all developmental stages (Fig. 2). The size
of our cDNA matches that of the corresponding mRNA rela-
FIG. 1. Protein sequence alignment among dTAFII16, dTAFII24,
and hTAFII30. Identical residues are shaded. Note the high sequence
conservation toward the C terminus. Accession numbers for dTAFII16
and dTAFII24 are AJ237968 and AJ276419, respectively.
FIG. 2. dTAFII16 expression. (A) Developmental Northern blot hybridized with the 502-nucleotide adult head cDNA probe. (B to F) Confocal
images of immunostaining with a crude anti-dTAFII16 rabbit serum (B to E) or a monospecific anti-dTAFII16 antibody (F) visualized by
fluorochrome Cy3. (B) Preblastoderm stage during cellularization. (C) Blastoderm stage. (D) Embryo stage 15 showing the central nervous system,
muscles, and epidermis. (E) Third-instar imaginal wing disk. Note the nuclear localization of the signal in all tissues and developmental stages. (F)
Detail of two Malpighian tubule cells. Note the spotty signal within the nucleus, except for the nucleoli, and its absence from the cytoplasm. Bar,
12 mm (B), 130 mm (C), 190 mm (D), 30 mm (E), and 2 mm (F).
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tively well, after allowing for poly(A) tracts. The broad band
indicates a size of 530 to 700 bp and suggests different levels of
polyadenylation. To resolve the cellular localization of the
protein, we stained larvae with a monospecific anti-dTAFII16
antibody using the preimmune serum as a negative control.
The specific signal was detected exclusively in the nuclei of all
cell types at all developmental stages including the blastoderm
prior to cellularization (Fig. 2). At variance with a recent
report (19), we failed to detect any cytoplasmic signal. To
address this discrepancy, we transfected cells with an expres-
sion vector containing myc-tagged dTAFII16 and stained them
with an anti-myc antibody (see below). This procedure con-
firmed the nuclear localization (data not shown). Within the
nucleus, dTAFII16 is localized in multiple hot spots, leaving a
single (occasionally double) major signal-deprived site that
seems to correspond to the nucleolus (Fig. 2F).
The PDS-dTAFII16 interaction is reproduced in vitro and in
vivo. The isolation of a large number of identical interactors in
the yeast two hybrid assay suggested that their binding is rel-
evant. To further analyze the association of PDS and dTAFII16,
we carried out GST pull-down and coimmunoprecipitation
(co-IP) assays. For the in vitro GST pull-down experiment,
dTAFII16 was tagged with histidine (His-dTAFII16) and PDS
was fused to GST. His-dTAFII16 was eluted through two types
of agarose columns, with bound GST-PDS or GST alone. The
experiment was performed three times, yielding reproducible
results. His-dTAFII16 binds to GST-PDS but fails to bind to
GST alone (Fig. 3A), indicating that the interaction is specific,
at least in this in vitro assay. In vivo evidence for this
association was obtained in a co-IP assay (Fig. 3B). Two
types of plasmids expressing myc-tagged dTAFII16 (myc-
dTAFII16) and hemagglutinin-tagged PDS (HA-PDS) were
used to transiently transfect Schneider 2 cells. The expression
of both proteins was verified in blots stained with antibodies
against myc and HA tags. Mouse monoclonal anti-myc and
rabbit polyclonal anti-HA antibodies were used for IP. Anti-
myc precipitates were probed with a rabbit polyclonal anti-
PDS (Fig. 3B, lane 1), stripped, and reprobed with anti-myc
antibody (lane 2). Conversely, precipitates elicited by rabbit
polyclonal anti-HA antibody were probed with a mouse mono-
clonal anti-HA and the anti-myc antibodies (lane 3). The data
show that anti-HA antibody precipitates myc-dTAFII16 when
coexpressed with HA-PDS and anti-myc antibody does so with
HA-PDS when coexpressed with myc-dTAFII16. Irrespective
of the antibody used to elicit IP, therefore, there is co-IP of the
other protein partner. As negative controls (data not shown),
in cell extracts transfected with single constructs, HA-PDS
precipitates with anti-HA but not with anti-myc whereas
myc-dTAFII16 precipitates only with anti-myc. These results
demonstrate that the PDS-TAFII16 association is specific and
takes place in living cells, most probably in the nucleus, where
both localize.
The interaction is mediated by the PDS HFD and the
dTAFII16 amino terminus. PDS contains a putative HFD be-
tween amino acids 12 and 82. In addition, abundant proline
residues are found C-terminal to this domain, albeit not clus-
tered in a recognizable motif. The yeast two-hybrid system
using eight different PDS fragments served to dissect the PDS
domain responsible for the interaction with dTAFII16 (Fig. 4).
The same control procedures as in the yeast two-hybrid screen
were used. All N-terminal fragments that included the first 90
amino acids of PDS were able to bind dTAFII16, whereas those
comprising only the C-terminal regions did not. In addition, a
small fragment including the HFD motif (PDS1–91) sustained
the interaction whereas fragments that split HFD (PDS1–47
and PDS40–124) did not. HFD thus appears necessary and suf-
ficient to mediate the binding between PDS and dTAFII16.
Although dTAFII16 is a small protein without recognizable
structural motifs, we attempted to identify a putative critical
region for the interaction with PDS. The three fragments used
(Fig. 4B) allowed identification of the N terminus as a require-
ment for this association. Attempts to further subdivide this
region failed to sustain the interaction.
FIG. 3. Physical association of PDS with dTAFII16. Abbreviations: (A) GST pull-down experiment between a GST-PDS fusion protein and
a histidine-tagged dTAFII16. (B) Coimmunoprecipitation of HA-tagged PDS with myc-tagged dTAFII16. The antibodies used for the immuno-
precipitation (IP) are indicated above each lane. The blot in lane 1 was probed with anti-PDS antibody, stripped, and reprobed with anti-myc
antibody (a-myc) (lane 2). The anti-PDS antibody thus reveals the HA-tagged as well as the constitutive PDS products. In lane 3, the precipitate
was induced with rabbit anti-HA antibody (a-HA) and then probed with mouse anti-HA antibody (see Materials and Methods) in addition to the
anti-myc antibody.
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PDS activates transcription in cells. To test the biological
significance of the interaction described above, we tested its
role in gene transcription by using transfected Schneider 2
cells. As a reporter, we monitored the enzymatic activity of
luciferase. The luciferase cDNA is under the control of the
herpes simplex virus thymidine kinase promoter fused to an
enhancer element containing five upstream activation se-
quence sites (Gal4 targets). lacZ under the control of the actin
promoter, which contains neither enhancers nor Gal4 sites,
served as an internal reference. The reporter and the internal
control were transfected in the absence or presence of plas-
mids driving the expression of Gal4-PDS, myc-dTAFII16, or
HA-TBP. Transfection with Gal4-PDS or myc-dTAFII16 had
no effect on luciferase activity with respect to basal levels.
Transfection with HA-TBP, alone or in addition to myc-
dTAFII16 or Gal4-PDS, led to relatively weak activation. Fol-
lowing cotransfection with the three proteins (Gal4-PDS,
myc-dTAFII16, and HA-TBP), however, a strong increase in
luciferase activity (18-fold with respect to the basal level) was
detected (Fig. 5A). The experiment was reproduced four
times, yielding consistent results. The activation levels ob-
served with the three proteins are equivalent to those reported
in a similar experiment using the transcriptional activator SplA
(see Fig. 3C in reference 25). Transfection with Gal4-PDS,
alone or in addition to mycTAFII16 or HA-TBP, failed to elicit
significant levels of activation. This observation would argue
against a role for PDS as a transcriptional activator, since the
endogenous TFIID components, including TAFII16 which is
expressed in Schneider 2 cells (data not shown), may have
contributed to the putative role of PDS. It should be noticed,
FIG. 4. Dissection of the interaction of PDS and dTAFII16 in
yeast. (A) Interaction of PDS fragments with dTAFII16. The HFD
motif in PDS extends from amino acids 12 to 82. (B) Interaction of
dTAFII16 fragments with PDS.
FIG. 5. PDS and dTAFII16 mediate transcription activation.
Schneider 2 cells were cotransfected with PDS, TAFII16, and TBP in
various combinations of tagged products (see the text). A 5-mg sample
of each plasmid DNA was used. Histogram values indicate the re-
corded luciferase activity normalized with respect to the internal con-
trol of b-galactosidase (b-gal) (see Materials and Methods). Basal
activity refers to the data obtained after transfection with luciferase-
and lacZ-containing plasmids. (A) Assays with full-length PDS fused to
Gal4BD. (B) Assays with a PDS fragment that includes the HFD
motif. HSV Tk, herpes simplex virus thymidine kinase.
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however, that the transcriptional activity of the luciferase re-
porter in this type of cell depends on the high expression levels
of the transfected plasmids. It is quite likely that if any one of
the required components is present at low concentration, it will
become a limiting factor. In fact, this is the key feature on
which this test is based. Comparing the activation levels elic-
ited by each protein combination, we can conclude that PDS
is able to activate transcription when fused to Gal4 using
dTAFII16 as a cofactor. This experiment provides additional
evidence on two important issues, (i) that the PDS-TAFII16
interaction occurs in vivo and (ii) that dTAFII16 is a bona fide
TAFII because it requires TBP to promote gene transcription.
In line with the data from the yeast two-hybrid test, we
assayed whether a PDS fragment containing the HFD motif
will be able to activate transcription of the luciferase reporter;
Fig. 5B shows that this is the case. The same small PDS frag-
ment, PDS1–91, used in the yeast two-hybrid tests yielded sig-
nificant activation only if co-transfected with TAFII16 and
TBP. This result demonstrates that the activation effect ob-
served with the whole PDS protein can be reproduced (70%
activation with respect to the whole PDS protein) by a frag-
ment including the HFD motif, further supporting the role of
this structural motif in the interaction with dTAFII16. The data
obtained so far indicate that the function of PDS in Drosophila
might be to activate gene transcription by recruiting dTFIID
components.
PDS and dTAFII16 modulate phenotype expression in Dro-
sophila. The expression of a constitutively active Ras1 allele
under the control of eye-specific sevenless regulatory sequences
(sev-Ras1V12) resulted in the transformation of cone cells into
R7 photoreceptors, which roughen the eye (compare Fig. 6A
and C) (17). This effect has been instrumental in isolating
components of the Ras1 signaling pathway (33). Mutations that
modify this phenotype are candidate genes for components of
the Ras1 signaling cascade or transcription factors that control
the expression of the sev-Ras1V12 construct or its downstream
genes. In this way, several TAFIIs have been identified as
mutant suppressors of the rough eye phenotype (60). We used
the same approach to test the potential effects of PDS and
dTAFII16. The data show that the sev-Ras1
V12 phenotype is
modulated by PDS in a gene dosage-dependent manner. Het-
erozygotes for mutant alleles (pds2270 and pds88) or deletions
[Df(1)88-6 and Df(1)88-2] of the gene partially suppressed
the eye roughening (Fig. 6B), whereas increased expression
of PDS (Fig. 6D and E) using one or two copies of a pds1
transgene (see Materials and Methods) progressively aggra-
vated it. The suppression effect was also observed in heterozy-
gotes of dTAFII16 deletions [Df(2)N6 and Df(2)N19] (Fig. 6F).
In this case, however, increased dosage could be assayed since
dTAFII16
1 transgenes are not yet available. The combined
reduction of gene dosage for PDS and dTAFII16 did not show
further suppression of the sev-Ras1V12-induced eye phenotype
FIG. 6. PDS and dTAFII16 modulate the phenotypic expression of a sev-Ras1
V12 construct. Representative scanning electron micrographs of
eyes of adult females expressing one copy of the sev-Ras1V12 construct with variable number of pds1 gene copies. (A) Wild type; (B) pds2270/1;
CyO-CR2, sev-Ras1V12/1; (C) CyO-CR2, sev-Ras1V12/1; (D) CyO-CR2, sev-Ras1V12/1;T(3)E6L/1; (E) CyO-CR2, sev-Ras1V12/1;T(3)E6L/ T(3)
E6L; (F) CyO-CR2, sev-Ras1V12/Df(2) N6. Numbers 1 to 4 above each panel indicate the number of functional copies of pds1 in the corresponding
genotypes. Note the pds gene dosage dependence of the eye-roughening phenotype. Also note in panel F the partial suppression elicited by the
heterozygous deletion for dTAFII16. Consistent results were obtained with other pds
2 [Df(1)88-6 and Df(1)88-2] or dTAFII16
2 [Df(2)N19]
chromosomes (data not shown). Anterior is to the left, dorsal is up. Bar, 90 mm. The diagram shows the structures of the three eye-roughening
producing constructs assayed.
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(data not shown). Taken together, these observations indicate
that both proteins act through the same mechanism or path-
way.
In an attempt to discriminate between PDS and dTAFII16
affecting sev-Ras1V12 transcription or the subsequent signaling
cascade, we assayed two other available constructs, sE-Raf torY9
and sev-hsp-ro. The three constructs differ in the enhancer/
promoter sequences or the gene driven (Fig. 6). The previous
gene dosage genotypes involving PDS or dTAFII16 show no
modification of the eye phenotype elicited by either construct
(data not shown). Since Ras1 and Raf activate the same or very
similar pathways, it is unlikely that the differential effect ob-
served with these two constructs could be attributed to a se-
lective effect of PDS and dTAFII16 on genes in the cascade.
Similarly, the lack of effect the sev-hsp-ro construct points to
the sev promoter as a likely target for PDS-dTAFII16. Since the
genomic segments containing the sev enhancers are not iden-
tical between the first two constructs, however, sev enhancers
cannot be formally excluded as a target for PDS-dTAFII16. To
further explore the role of PDS on transcription activation, and
in particular whether PDS could target the sevenless promoter
or enhancer sequences, we assayed a novel luciferase-express-
ing construct, sev-luc, containing the same regulatory se-
quences as the sev-Ras1V12 construct (see Materials and Meth-
ods). No significant effect on luciferase expression was found in
cells transfected with PDS, dTAFII16, TBP, or their combina-
tions (data not shown). This result indicates that PDS is un-
likely to be a transcriptional activator per se or, alternatively,
that its native target is not included in the sev-promoter/sev-
enhancer sequences. Nonetheless, since both the Gal4-driven
luciferase transcription in cells and the sev-driven Ras1 phe-
notypes in flies indicate that PDS plays a role in activation, it
can be concluded that PDS is a coactivator that recruits com-
ponents of the TFIID and requires an additional mechanism to
bind DNA.
Exploring interactions with other TFIID components.
hTAFII30 is reported to interact with TBP, hTAFII250,
hTAFII20, and itself, forming homomultimeres (32). Using the
yeast two-hybrid system, we tested whether dTAFII16 could
interact with dTBP, dTAFII30a (the Drosophila homologue of
hTAFII20), or itself. All these assays yielded negative results
(data not shown), suggesting that hTAFII30 and dTAFII16 do
not sustain the same interactions within TFIID. EST database
searches revealed another Drosophila EST (accession number
AI457031), however, encoding a protein very similar to dTAFII16
and hTAFII30. The gene maps to the 23A6-7 chromosome band,
adjacent and in opposite orientation to dTAFII16. We sequenced
this genomic region and the EST in full to confirm the ORF.
The revised sequence has been submitted to the EMBL data-
base (accession number AJ276419). It indicates a second
hTAFII30 homologue, with a theoretical molecular mass of
18.5 kg mol21. Both Drosophila homologues of hTAFII30 have
been reported recently, and the name dTAFII24 was assigned
to the second element (19). Given the similarity between
dTAFII16 and dTAFII24, we used the yeast two-hybrid assay to
find whether PDS would interact with the new homologue; the
result was negative. In addition, since the N terminus of
dTAFII16 mediates the interaction with PDS (Fig. 4B) and
since both dTAFIIs deviate in their N-terminal sequences (Fig.
1), it is likely that this part of the protein sustains differential
interactions of these TAFIIs. These results demonstrate that
dTAFII16 and dTAFII24 are functionally distinct. Neverthe-
less, we further assayed whether dTAFII16 and dTAFII24
could interact in Drosophila, mimicking the reported homo-
dimerization of hTAFII30. The result from the yeast two-hy-
brid assay was, however, negative (data not shown). The same
experimental approach also yielded a negative result to the
question whether PDS could interact directly with TBP. This
last observation is coherent with the requirement for the triple
cotransfection (PDS, dTAFII16, and TBP) in the transcription
activation assays (Fig. 5).
pds function is required for cell survival. The cellular effects
of PDS depletion can be evaluated in mosaics. To that end,
transheterozygous y w pds2270/f 36a larvae were irradiated to
obtain marked twin spots screened in the dorsal notum. In
addition, y w pds2270/M(1)n larvae were similarly treated to
generate w pds2270 M1 clones marked in the eye. No mutant
clones were detected in either system, and control cases ap-
peared at the expected ratios (Table 1). It should be noted that
mutant eye cells, which are M1, would have had a growth
advantage over the surrounding cells (15). These data demon-
strate that PDS is a cell vital function, at least for integument
cells.
DISCUSSION
The data show that Drosophila PDS and TAFII16 interact
specifically, leading to transcription activation through the
TFIID complex. The structural motifs in each protein that
mediate the interaction have been dissected, and the results
indicate that PDS should be considered a coactivator of gene
expression. Since PDS is a vital cell function and since both
proteins are expressed in all cell types, it can be deduced that
the interaction is functional in many genes. In addition, since
both proteins appear to have conserved homologues and re-
quirements, their interaction is expected to be functional in
mammals as well.
Functional interaction of the HFD. PDS fragments that con-
tain the HFD motif sustain the PDS-dTAFII16 association,
demonstrating that this is a functional domain. For the other
partner, dTAFII16, the N terminus is necessary and sufficient
for the interaction to take place. HFD is a motif conserved in
all core histones and several TAFIIs. It is formed by a long
central a-helix flanked by two smaller ones. The central helix
TABLE 1. pds somatic mosaicsa
Region Locus No. of clones
Notum f 36a 19
y 2 f 36a 2
y 3
Eye w pds 0
Control 17
a Notum clones marked with f 36a result from crossovers between this marker
and the centromere. An equivalent number of y-marked twins was expected if pds
was a viable mutation. The only two cases of y 2 f 36a twins detected must
correspond to crossovers between pds and f 36a loci. Clones marked with y result
from crossovers distal to f 36a. The sizes of all clones ranged from one to four
bristles. Eye clones marked with w are also M(1)n1 and must include pds.
Control clones in the eye are scored on Dp(1;3)JC153 bearing siblings. This
duplication carries a normal copy of pds gene.
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acts as a dimerization interface in a head-to-tail fashion de-
scribed as a “handshake” structure (2, 76). To date, most
HFD-mediated interactions have been documented between
proteins containing the same motif. A precedent for interac-
tion between HFD- and non-HFD-containing proteins is,
nonetheless, known for the trimeric CBF/NF-Y transcription
factor (41). The case of PDS-dTAFII16 reported here would
add another such example. Current databases include over
1,000 HFD-containing proteins (5), suggesting that the number
and diversity of processes mediated by this motif will increase
substantially.
The association has been reproduced both in vitro and in
vivo, showing that it is specific and functionally relevant for
gene transcription. Further, the luciferase transcription assay
demonstrates that the functional expression of this interaction
also requires TBP. This result argues in favor of TFIID as the
likely transcription factor through which PDS elicits transcrip-
tion activation. dTAFII16 has recently been shown to partici-
pate in TFIID but not in other complexes (19). Moreover, the
absence of dTAFII16 from nucleoli is consistent with the fact
that ribosomal gene transcription does not involve TFIID.
Two conserved proteins, PDS and dTAFII16. pds is a recently
discovered Drosophila gene (our unpublished data) (accession
number Y15513). Databases also include the murine protein
Taube nuss (accession number AAG01682), which is 35%
identical to PDS and has an HFD motif toward its N terminus
(Fig. 7). In addition, we found that PDS is a vital cell function
in Drosophila and Taube is reported to be essential for pluri-
potent cells in the mouse. Based on these structural and func-
tional features, it is likely that the two proteins are homo-
logues. Among human database sequences, a clot (Hs. 139179)
of eight ESTs (accession numbers AI151131, AI027324,
AI027325, AI655948, AI738942, AA983184, AA641254, and
N71758) also shows close homology to the Drosophila PDS.
Although dTAFII16 and dTAFII24 are considered sequence
homologues of hTAFII30, detailed analysis of the three protein
sequences indicates that dTAFII16 is a closer relative of
hTAFII30 (45% identity) than of dTAFII24 (38% identity).
The two protein sequences diverge in their N terminus, and
this is the region that mediates the selective interaction
dTAFII16-PDS. It thus seems that the two TAFIIs are func-
tionally different in Drosophila. In this context, specific mutant
traits would be expected for these two genes, although no
mutations have thus far been identified in either of them to
confirm this point. We used PCR to analyze all available lethal
mutations in the area [l(2)AB2, l(2)AB3, l(2)AB4, l(2)AB5, and
l(2)AB6] (10, 39), and none showed sequence alterations in the
ORF or the genomic regions of either dTAFII. The chromo-
some Df(2)N6 is the only genetic variant available, and it
deletes both dTAFII genes. Since additional genes are in-
cluded, however, the lethality of this chromosome cannot be
attributed unequivocally to the dTAFII genes.
In addition to the sequence conservation and its functional
association with TBP for gene transcription, dTAFII16 local-
izes to the nucleus at all developmental stages and tissues, as
do all other TAFIIs. In this context, we cannot confirm the
reported dual nuclear and cytoplasmic localization of dTAFII16
(19). It may be relevant that the antibodies used in the previous
study were raised against peptide sequences whereas those
used here were obtained after immunization with the whole
protein. Data based on monospecific antibodies, crude serum,
and labeling of myc-tagged dTAFII16 localize the signal in
multiple spots within the nucleus only (Fig. 2). The hot spots at
which dTAFII16 appears to accumulate may correspond to
transcriptionally active regions.
Molecular mechanism and biological function of PDS.
Transfection experiments in Schneider 2 cells show that PDS
activates transcription when fused to the Gal4 DNA binding
domain in a dTAFII16- and TBP-dependent manner. The gene
dosage effects on the expression of a Ras1 construct also sup-
port the role of PDS as an activator rather than a repressor. In
principle, this function could be achieved either as a bona fide
transcription activator binding directly to DNA and recruiting
TFIID to specific promoters or as a cofactor linking a true
activator to the transcription complex. Several arguments sup-
port PDS as a cofactor for gene transcription. Cells transfected
with PDS only fail to activate transcription of the luciferase
reporter from the sev-Luc construct. This experiment was de-
signed to test whether PDS could use enhancer or promoter
sequences from the sevenless gene as target, in view of the
effects observed on the eye phenotype of sev-Ras1V12 and the
pds gene dosage. It thus appears that to activate transcription,
PDS requires association with a DNA-binding activator. In the
experiments with the upstream activation sequence-Luc con-
struct (Fig. 5), this effect was provided by the DNA-binding
domain of Gal4. This procedure of tethering proteins to a
promoter has served to infer a role of coactivators for many
components of several transcriptional complexes (20, 34, 62).
The gene dosage modulation of the eye phenotype is probably
FIG. 7. Protein sequence alignment between PDS and the recently
reported murine protein Taube nuss. Identical residues are shaded.
Note the presence of a HFD domain (shaded) in both proteins. Ac-
cession numbers for PDS and Taube are Y15513 and AAG01682,
respectively.
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due to the titration effect on native components of the tran-
scription machinery.
Through which transcription complex does PDS function?
Extensive biochemical work on preinitiation complex purifica-
tion in several organisms has failed to identify PDS so far,
suggesting that PDS is not a constitutive member of TFIID,
and we have shown here that PDS does not interact with TBP
directly. These features prevent consideration of PDS as a
TAF, at least formally. Taken together, the available data
indicate that PDS is a novel transcriptional coactivator in
which HFD is the functional domain that mediates the inter-
action with dTAFII16; this mechanism underlies a biological
function essential for cell survival. This observation, in addi-
tion to its generalized expression in all tissues throughout de-
velopment, as well as its conserved sequence and requirement
for cell survival, suggests that many genes will be the target of
PDS-mediated activation.
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